Malignancy Spectrum最新文献

{"title":"Correlation of the fibroblast growth factor-inducible 14 receptor and progranulin as prognostic biological markers in ductal invasive breast cancer: Immunohistochemical study","authors":"Mona A. H. Yehia,&nbsp;Sabah A. Al-Qadasi,&nbsp;Amel S. Al-Sedfy,&nbsp;Noura A. K. Matar","doi":"10.1002/msp2.70000","DOIUrl":"https://doi.org/10.1002/msp2.70000","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The Fn14 fibroblast growth factor-inducible 14 (Fn14) can stimulate cell migration and promote cancer lessions. Progranulin (GP88) protein has been identified as an epidermal growth factor and participates in many biological processes. The aim of the present work was to investigate the immunohistochemical expression of Fn14 and GP88 proteins in relation to the clinical parameters in women's invasive ductal carcinoma (IDC) and to explore their role as novel prognostic biomarkers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The qualitative and quantitative immunohistochemical techniques were used to evaluate the expression levels of Fn14 and GP88 in 100 fresh samples of Egyptian women who had breast lesions. They were divided into three groups: control healthy tissues (10 samples from woman lesions), benign group (30 cases), and IDC group (60 cases).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The histopathological results of 60 cases with IDC have been reported with 45 cases being grade Ⅱ and 15 cases being grade Ⅲ. The immunohistochemical results showed that the degree of strong positive staining for both markers was increased in grade Ⅲ compared to that in grade Ⅱ. The integrated optical density was significantly increased in grade Ⅲ (<i>p</i> &lt; 0.05). Also, the result revealed a highly significant correlation between the two markers and the tumor size, grades, and lymph node metastasis, as well as a correlation to normal and benign breast lesions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The quantitative immunohistochemistry of Fn14 and GP88 proteins revealed the correlation between the two markers and clinical parameters. Therefore, the two markers may be serviceable as prognostic and therapeutic markers in IDC patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 1","pages":"26-36"},"PeriodicalIF":0.0,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70000","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vitro and in vivo evaluation of the cyclophosphamide effect along with oncolytic Newcastle disease virus (NDV): An animal preclinical research","authors":"Mohammad Reza Foroughi-Gilvaee,&nbsp;Alireza Jahandideh,&nbsp;Mohammad Faranoush,&nbsp;Reza Nekouian","doi":"10.1002/msp2.57","DOIUrl":"https://doi.org/10.1002/msp2.57","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Breast cancer is a major cause of mortality globally. Oncolytic virotherapy is a promising treatment modality that directly destroys cancer cells and induces an immune response against them. Among natural oncolytic viruses, Newcastle disease virus (NDV) has shown selective tumor cell infection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and methods</h3>\u0000 \u0000 <p>In this study, we investigated the efficacy of variable doses of NDV and cyclophosphamide on 4T1 cancer cell line and BALB/c mouse tumors for the first time.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Compared with the control group, the combination treatment group with NDV and cyclophosphamide showed a significant increase in the expression levels of <i>P21</i>, <i>P27</i>, and <i>P53</i> genes by 38%, 46%, and 81%, respectively (<i>p</i> &lt; 0.05). In contrast, the expression levels of <i>CD34</i>, <i>integrin α5</i>, vascular endothelial growth factor (<i>VEGF</i>), and vascular endothelial growth factor receptor (<i>VEGFR</i>) genes significantly decreased by 47%, 45%, 42%, and 23%, respectively (<i>p</i> &lt; 0.05). The reactive oxygen species (ROS) generation assay evaluated with 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) staining showed a significant increase in ROS levels within 4T1 cells treated with NDV compared with the untreated group after 24 h (<i>p</i> &lt; 0.01). Furthermore, Annexin V/propidium iodide (PI) double staining analysis showed that the proportion of apoptotic cells in the NDV-treated group decreased by 0.61% and 1.63% after 6 h and 12 h, respectively (<i>p</i> &lt; 0.05). After 12 days, tumor volume in the NDV-treated groups decreased by 72%−87% compared with a 48% increase in the control group, reflecting a net reduction in tumor volume relative to the control group (<i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These findings demonstrate that NDV in combination with chemotherapy drugs may be a promising therapeutic option for cancer patients. However, several other factors need to be considered. These results indicate that NDV may have potential effects on cancer treatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 1","pages":"13-25"},"PeriodicalIF":0.0,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.57","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143740986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing tumor radiotherapy sensitivity through metal nanomaterials: A comprehensive review","authors":"Susu Xiao,&nbsp;Xiaoxiao Wang,&nbsp;Bo Chen,&nbsp;Min Mu,&nbsp;Bo Han,&nbsp;Nianyong Chen,&nbsp;Gang Guo","doi":"10.1002/msp2.52","DOIUrl":"https://doi.org/10.1002/msp2.52","url":null,"abstract":"<p>Radiotherapy (RT) plays a crucial role in tumor treatment and is an indispensable therapeutic approach. However, ionizing radiation often damages the normal tissues surrounding the tumor. Therefore, there is an urgent need for effective methods to improve the precision of RT. Nanotechnology has shown potential in enhancing the efficacy and safety of tumor RT. With the continuous development of multifunctional nanomaterials, various nanomaterials have been designed and investigated as radiation enhancers. Metallic nanomaterials are considered as promising radiosensitizers with potential for clinical translation. High atomic number (high-Z) metal nanoparticles (NPs), such as gold and bismuth, have garnered increasing attention for their ability to enhance the radiation effect, as they can potentially improve RT outcomes. New nanomedicine strategies may help to advance RT. This paper concisely explains the radiation enhancement mechanisms of high-Z metal NPs. It also enumerates several commonly studied high-Z metallic nanomaterials used in tumor RT and discusses their potential clinical applications.</p>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"1 4","pages":"243-262"},"PeriodicalIF":0.0,"publicationDate":"2024-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.52","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143253665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of 3D printing template-assisted CT-guided radioactive iodine-125 seed implantation for peripheral locally recurrent rectal cancer: A retrospective study","authors":"Xuemin Li,&nbsp;Hao Wang,&nbsp;Yuliang Jiang,&nbsp;Zhe Ji,&nbsp;Haitao Sun,&nbsp;Jinghong Fan,&nbsp;Weiyan Li,&nbsp;Junjie Wang","doi":"10.1002/msp2.55","DOIUrl":"https://doi.org/10.1002/msp2.55","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This study aimed to investigate the accuracy of needle insertion and dosimetric parameters in three-dimensional printing template (3D-PT)-assisted computed tomography (CT)-guided radioactive iodine-125 (&lt;sup&gt;125&lt;/sup&gt;I) seed implantation (RISI) for the treatment of peripheral locally recurrent rectal cancer (pLRRC).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Materials and methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A total of 37 patients with pLRRC who underwent 3D-assisted CT-guided RISI treatment at Peking University Third Hospital between January 2016 and November 2019 were included in this study. All patients underwent preoperative assessment, CT simulation positioning, preoperative plan design, 3D template printing, 3D template reduction, needle and seed implantation, postoperative dosimetry evaluation, postoperative care, and regular follow-up. The preoperative and postoperative needle position, angle, and tip distance were compared. The dosimetric parameters, including D90 (the dose to 90% of the target volume), D100, V100 (the volume receives 100% of the prescribed dose), V150, V200, conformal index (CI), external index (EI), and homogeneity index (HI), were compared among preoperative plan, intraoperative plan, and postoperative plan. The perioperative complications were assessed.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The total number of needles was 595. The depths of needle insertion in preoperative and intraoperative plans were 109.87 ± 1.33 mm and 108.46 ± 1.26 mm, respectively, with no significant difference (&lt;i&gt;p&lt;/i&gt; &gt; 0.05). The angles of needle insertion in preoperative and intraoperative plans were (93.55 ± 2.05)° and (92.04 ± 1.99)°, respectively, with no significant difference (&lt;i&gt;p&lt;/i&gt; &gt; 0.05). The average deviation of the needle insertion distance was 1.99 ± 0.08 mm. There were no differences in preoperative, intraoperative, and postoperative parameters, including D90, D100, V100, V150, V200, CI, EI, and HI. All patients were closely followed up during the perioperative period (from seven days before surgery to seven days after surgery). No patients experienced severe perioperative complications. A total of eight patients (21.6%) experienced grade 1−2 complications. Among all patients, six individuals (16.2%) experienced pain, one patient (2.7%) had a fever, and one patient (2.7%) suffered from a hemorrhage. All patients recovered after conservative treatment.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The needle insertion in 3D-PT-assisted CT-guided RISI showed good accuracy for treating pLRRC.&lt;/p&gt;\u0000 ","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"1 4","pages":"323-331"},"PeriodicalIF":0.0,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.55","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143253392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of risk prediction scores for venous thromboembolism in ambulatory cancer patients with solid tumors receiving chemotherapy: A comparative analysis","authors":"Hamsaveni Muthukumar,&nbsp;Wesley Mannirathil Jose,&nbsp;Nikhil Krishna Haridas,&nbsp;Anjali Sajikumar Nair,&nbsp;Keechilat Pavithran","doi":"10.1002/msp2.54","DOIUrl":"https://doi.org/10.1002/msp2.54","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Cancer patients have a 4−7-fold increased risk of thrombotic complications due to cancer as well as chemotherapy-induced hypercoagulable state. This study compared the different risk assessment models (Khorana, PROTECHT, CONKO, and COMPASS-CAT scores) that help predict venous thromboembolism (VTE) in ambulatory cancer patients. Early identification of high-risk patients would benefit from thromboprophylaxis, thereby improving the mortality and morbidity due to thrombotic events.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This is a single-center, prospective, cross-sectional study on ambulatory patients with solid malignancy. The study was conducted over six months, from March 2022 to August 2022. Data on VTE predictors were gathered from 230 ambulatory cancer patients undergoing chemotherapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among the 230 patients receiving chemotherapy, 20 were diagnosed with VTE, with the majority of this population being either diagnosed with gynecological cancer or lung cancer, constituting 25% of VTE-diagnosed patients. The Khorana score, with a VTE accuracy of 83.04%, was found to be the highest, followed by the CONKO (80.00%), PROTECHT (69.57%), COMPASS-CAT Ⅱ (54.35%), and COMPASS-CAT Ⅰ (38.26%) scores. The cumulative incidence of VTE among high-risk patients showed that the PROTECHT score had the highest cumulative incidence (CI = 14.28), and the CONKO score had the lowest (CI = 9.40).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The Khorana score was the most accurate, followed by the CONKO, PROTECHT, and COMPASS-CAT Ⅱ scores, while the COMPASS-CAT Ⅰ score was the least accurate. Hence, the Khorana scoring is essential for diagnosing VTE in patients with ambulatory cancer treated with chemotherapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"1 4","pages":"332-338"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.54","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143253054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The mechanistic role of curcumin and its analogs in NSCLC: An evaluation of cell death in preclinical studies","authors":"Ela Kesen Boztas,&nbsp;Sevki Mustafa Demiroz,&nbsp;Hacer Ilke Onen","doi":"10.1002/msp2.53","DOIUrl":"https://doi.org/10.1002/msp2.53","url":null,"abstract":"<p>Lung cancer is the leading malignancy among males and ranks the second in females, with an estimated two million new diagnoses annually. It ranks the first in cancer-related deaths among men and the second, following breast cancer, among women. The most significant risk factor for lung cancer is smoking. There are two main types of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with about 85% of cases falling into the NSCLC category. Even with a combination of treatments for NSCLC, such as surgical intervention, chemotherapy, radiation therapy, and immunotherapy, the 5-year survival rates for those diagnosed with advanced NSCLC have not reached satisfactory levels, with chemotherapy continuing to be the main therapeutic approach. In advanced NSCLC treatment, gemcitabine and platinum-based agents are applied as first-line therapy. However, acquired or pre-existing drug resistance can prevent chemotherapeutic agents from achieving the expected effect on patients and increasing the drug dose can lead to an increase in side effects. In recent years, for these reasons, there has been an increased interest in phytochemicals to enhance the cytotoxic effects of therapeutic agents on cancer cells while minimizing their toxic effects on healthy tissues. One of the most studied phytochemicals is curcumin. Despite its anticancer effects on NSCLC cells, its low stability and poor pharmacokinetics have led to unsatisfactory results in studies. Therefore, a variety of analogs have been synthesized. This review explores the impact of curcumin and its analogs on the pathways of cell death in NSCLC.</p>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"1 4","pages":"263-274"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.53","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143252915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update on immunotherapy-mediated colitis: Clinical features, mechanisms, and management","authors":"Dandan Wang,&nbsp;Yiwei Zhao,&nbsp;Yiyun Zeng,&nbsp;Lanlin Hu,&nbsp;Chuan Xu","doi":"10.1002/msp2.50","DOIUrl":"https://doi.org/10.1002/msp2.50","url":null,"abstract":"<p>Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has radically transformed the field of oncological therapy. However, immune-related adverse events (irAEs) associated with the treatment might affect the life quality and even threaten the life of cancer patients. Immunotherapy-mediated colitis (IMC) is one of the most prevalent irAEs, especially in anti-cytotoxic T lymphocyte antigen 4 antibody (CTLA4) therapy. Current management of IMC includes administering immunosuppressants and discontinuing the treatment, which might affect the therapeutic efficacy. In this review, we briefly summarize the development of ICIs in cancer immunotherapy and the incidence, diagnosis, and management of IMC. Recent insights into the cellular and molecular pathways that underpin IMC, perspective research, and promising therapeutic strategies are highlighted. Further understanding of IMC and its implications will assist clinicians in optimizing treatment strategies to mitigate this side effect while maximizing the benefits of ICIs.</p>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"1 4","pages":"225-242"},"PeriodicalIF":0.0,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.50","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143252636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A retrospective observational study of patients with melanoma prescribed combined BRAF and MEK inhibitors in a real-world treatment setting in Japan","authors":"Kenjiro Namikawa,&nbsp;Kok Yew Ngew,&nbsp;Zuzanna Lukowicz,&nbsp;Ryosuke Kano","doi":"10.1002/msp2.51","DOIUrl":"https://doi.org/10.1002/msp2.51","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to describe patients with melanoma initiating treatments with dabrafenib plus trametinib (Dab + Tram) or encorafenib plus binimetinib (Enco + Bini) in a real-world setting in Japan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data were extracted from the Japanese Medical Data Vision (MDV) insurance claims database. Patients diagnosed with melanoma between 2012 and 2021 and prescribed with Dab + Tram or Enco + Bini were included in three cohorts: non-adjuvant Dab + Tram, adjuvant Dab + Tram, and Enco + Bini. Data were extracted on patient characteristics at treatment initiation. During follow-up, all changes in melanoma treatments were documented. Treatment adherence was determined as the proportion of prescription days covered (PDC) and treatment dose intensity as the relative dose intensity (RDI).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Sixty-seven patients were included in the non-adjuvant Dab + Tram cohort (55 first-line treatments), seven in the adjuvant Dab + Tram cohort (six first-line treatments), and 16 in the Enco + Bini cohort (four first-line treatments). The mean age was 61.3 ± 13.5 years and 56.1% were men. Twenty-seven patients with non-adjuvant Dab + Tram or Enco + Bini in first line (45.8%) switched to a second line. The median treatment duration was 11.8 months for Dab + Tram and 8.1 months for Enco + Bini. A PDC ≥ 80% was observed for 85.7% of patients with adjuvant Dab + Tram, 68.7% for non-adjuvant Dab + Tram, and 75.0% for Enco + Bini. Median RDI was 1.0 for adjuvant Dab + Tram, 0.9 for non-adjuvant Dab + Tram, and 0.6 for Enco + Bini.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Dab + Tram is used consistently with clinical practice guidelines in the adjuvant setting, but adherence in the non-adjuvant setting is suboptimal, as is the prescribed dose of Enco + Bini. Prescribers should ensure that these therapies are used in an optimal way to improve outcomes in melanoma.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"1 4","pages":"312-322"},"PeriodicalIF":0.0,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.51","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143252508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary malignant melanoma of the breast: A case report without relapse","authors":"Alejandro Caballero,&nbsp;Mario Perez,&nbsp;Issis Rodriguez","doi":"10.1002/msp2.49","DOIUrl":"https://doi.org/10.1002/msp2.49","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to report the treatment and outcomes of a patient with primary malignant melanoma of the breast parenchyma using mastectomy as the main treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patient and methods</h3>\u0000 \u0000 <p>A 67-year-old female presented with a palpable lump approximately 2 cm in diameter in the lower inner quadrant of the left breast, and underwent ultrasound guided cutting needle biopsy. Cytological examination identified a malignant melanoma of the breast, and she received treatment with a modified radical mastectomy. Further assessment was carried out using a positron emission tomography/computed tomography, which negated the presence of a primary lesion in either adjacent or distant sites.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>After three years of follow-up with ultrasonography (USG) and mammography annually and a complete physical examination every six months in the clinic, the patient remained alive with no evidence of local or distant recurrence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The surgical management of this case is appropriate according to the available literature up to the present. We recommend <i>BRAF</i> mutation testing and melanocytic marker testing for all patients to ensure the correct focus when selecting biomarker-based immunotherapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"1 4","pages":"339-345"},"PeriodicalIF":0.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.49","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143253489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of genetic profile of breast carcinoma on MRI using a combination of DCE-MRI, DWI, and MR spectroscopy: A prospective observational study","authors":"Payal Sharma,&nbsp;Ishan Kumar,&nbsp;Ritu Ojha,&nbsp;Seema Khanna,&nbsp;Ashish Verma","doi":"10.1002/msp2.45","DOIUrl":"https://doi.org/10.1002/msp2.45","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Classification of breast cancer based on gene expression has emerged as the standard approach in its management, owing to the distinct prognoses and treatment responses observed among different subtypes. The aim of this study was to prospectively assess the imaging features of the molecular subtypes of breast cancer using multiparametric magnetic resonance imaging (mMRI) with the combined assessment of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), diffusion-weighted imaging (DWI), and MR spectroscopy (MRS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a prospective observational single-center cohort study, which included women with BI-RADS 4−5 lesions on mammography/ultrasound (US) who subsequently underwent 1.5 T MRI (encompassing DCE-MRI, DWI, and MRS). The histological subtypes of breast cancer were assessed. Estrogen receptor (ER), progesterone receptor (PR), Ki-67 status, and human epidermal growth receptor-2 (HER2) expression, assessed by immunohistochemistry (IHC), defined four molecular subtypes: luminal A, luminal B, HER2-enriched (Her2en), and triple-negative breast carcinoma (TNBC). Statistical associations between the four molecular subtypes and MRI features were investigated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Fifty patients were included in the study. Circumscribed margins were significantly correlated with triple-negative tumors compared to others (78% versus 6%, <i>p</i> &lt; 0.001). Spiculated margins were observed in non-triple negative tumors. Rim enhancement was significantly correlated to triple-negative tumors compared to all other subtypes (71.4% versus 25%, <i>p</i> = 0.035). Mean apparent diffusion coefficient (ADC) values were significantly lower for luminal subtypes compared to non-luminal subtypes (<i>p</i> &lt; 0.001). The total choline (tCho) signal-to-noise ratio (SNR) was higher in triple-negative tumors. A combined algorithm using DCE-MRI, DWI, and MRS can predict TNBC and Her2en with specificity of 86.6% and 100%, respectively, and sensitivity of 100% and 85.37%, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The combination of mMRI with DCE-MRI, DWI, and MRS can accurately differentiate the molecular subtypes of breast carcinoma.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"1 4","pages":"290-299"},"PeriodicalIF":0.0,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.45","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143252514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}